uniQure N.V. Ordinary Shares QURE
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T18:53:59.281Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:53:16.947120911Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T18:51:49.451616+00:00
uniQure N.V. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 19.63 | 217.4% | 22.8% | |||
| 25Δ | 26.89 | 101.9% | 13.2% | 22.15 | 105.1% | 10.7% |
| 30Δ | 26.35 | 102.5% | 11.5% | 22.67 | 102.5% | 9.2% |
| 35Δ | 25.80 | 100.0% | 9.7% | 23.15 | 98.4% | 7.7% |
| 40Δ | 25.23 | 92.2% | 7.7% | 23.58 | 91.3% | 6.3% |
| 45Δ | 24.77 | 85.0% | 6.2% | 24.01 | 84.3% | 5.0% |
| 50Δ | 24.40 | 78.3% | 4.9% | 24.34 | 82.0% | 4.2% |
| 55Δ | 24.02 | 71.6% | 3.7% | 24.67 | 79.7% | 3.5% |
| 60Δ | 23.70 | 71.4% | 3.1% | 26.02 | 147.7% | 5.1% |
| 65Δ | 23.39 | 71.4% | 2.6% | 26.44 | 136.0% | 4.1% |
| 70Δ | 23.08 | 71.5% | 2.1% | 26.85 | 124.3% | 3.0% |
| 75Δ | 22.78 | 69.3% | 1.6% | 27.17 | 112.6% | 2.2% |
| 80Δ | 22.47 | 66.1% | 1.2% | 27.43 | 101.1% | 1.6% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.63
- IV
- 217.4%
- B/E move
- 22.8%
25Δ
- Pseudo strike
- 26.89
- IV
- 101.9%
- B/E move
- 13.2%
- Pseudo strike
- 22.15
- IV
- 105.1%
- B/E move
- 10.7%
30Δ
- Pseudo strike
- 26.35
- IV
- 102.5%
- B/E move
- 11.5%
- Pseudo strike
- 22.67
- IV
- 102.5%
- B/E move
- 9.2%
35Δ
- Pseudo strike
- 25.80
- IV
- 100.0%
- B/E move
- 9.7%
- Pseudo strike
- 23.15
- IV
- 98.4%
- B/E move
- 7.7%
40Δ
- Pseudo strike
- 25.23
- IV
- 92.2%
- B/E move
- 7.7%
- Pseudo strike
- 23.58
- IV
- 91.3%
- B/E move
- 6.3%
45Δ
- Pseudo strike
- 24.77
- IV
- 85.0%
- B/E move
- 6.2%
- Pseudo strike
- 24.01
- IV
- 84.3%
- B/E move
- 5.0%
50Δ
- Pseudo strike
- 24.40
- IV
- 78.3%
- B/E move
- 4.9%
- Pseudo strike
- 24.34
- IV
- 82.0%
- B/E move
- 4.2%
55Δ
- Pseudo strike
- 24.02
- IV
- 71.6%
- B/E move
- 3.7%
- Pseudo strike
- 24.67
- IV
- 79.7%
- B/E move
- 3.5%
60Δ
- Pseudo strike
- 23.70
- IV
- 71.4%
- B/E move
- 3.1%
- Pseudo strike
- 26.02
- IV
- 147.7%
- B/E move
- 5.1%
65Δ
- Pseudo strike
- 23.39
- IV
- 71.4%
- B/E move
- 2.6%
- Pseudo strike
- 26.44
- IV
- 136.0%
- B/E move
- 4.1%
70Δ
- Pseudo strike
- 23.08
- IV
- 71.5%
- B/E move
- 2.1%
- Pseudo strike
- 26.85
- IV
- 124.3%
- B/E move
- 3.0%
75Δ
- Pseudo strike
- 22.78
- IV
- 69.3%
- B/E move
- 1.6%
- Pseudo strike
- 27.17
- IV
- 112.6%
- B/E move
- 2.2%
80Δ
- Pseudo strike
- 22.47
- IV
- 66.1%
- B/E move
- 1.2%
- Pseudo strike
- 27.43
- IV
- 101.1%
- B/E move
- 1.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 109.12% | |
| 105.32% | |
| 101.65% | |
| 111.15% | |
| 100.89% | |
| 104.59% | |
| 102.08% | |
| 99.40% | |
| 97.64% | |
| 107.10% |
Biotechnology
RANI
Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the…
More →RAPP
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases, especially Alzheimer's and associated…
More →RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of…
More →RCKT
Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. The company is…
More →RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward,…
More →REGN
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their…
More →